About the Event
More than 200 million people suffer from inflammatory skin conditions like acne, rosacea, dermatitis, and psoriasis. The current standard of care, a course of steroids, often comes with strong negative side effects and is effective in fewer than 40 percent of patients.
AOBiome Therapeutics has developed a topical biologic spray that is effective in a broad array of inflammatory skin conditions. It is as a safe as a water, making it an excellent choice for a first line therapy for mild to moderate itch and inflammation.
Join our webinar with AOBiome President & CEO, Todd Krueger, as he discusses the company’s clinical results to date, their upcoming Phase 3 clinical trial, and the path to commercialization.